SkinTE™ in the Treatment of Diabetic Foot Wounds
Study Details
Study Description
Brief Summary
This study is a prospective, multi-center, randomized controlled trial designed to collect patient outcome data on a commercially available human autologous homologous skin construct with SOC dressing compared to SOC dressings alone in the treatment of Diabetic Foot Wounds.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This study is a prospective, multi-center, Randomized Controlled Trial ( RCT ) designed to collect patient outcome data on a commercially available human autologous homologous skin construct (SkinTE™) with SOC dressing compared to SOC dressings alone in the treatment of Diabetic Foot Wounds (DFU) .The trial will be single blinded in regard to wound healing assessment (another clinician, other than the investigator at each site will assess wound healing) and confirmation of wound healing will be overseen by an independent adjudication committee made up of wound care experts. The study will last thirteen weeks, with a two week screening period prior to enrollment.
There are two arms in the study:
Arm 1: The Experimental Arm , that will include SOC Therapy. SOC therapy in this study is offloading of the DFU (CAM boots or total contact casting [TCC] if the subject's foot is too large for a CAM), appropriate sharp or surgical debridement, infection management (systemic antibiotics only in conjunction with debridement) and the experimental wound care covering with human autologous,homologous skin construct (SkinTE™ followed by a moisture retention dressing and a padded 3-layer dressing comprised of 4x4 gauze pads, soft roll and compression wrap (DynaflexTM or equivalent).
Arm 2: The Standard of Care Arm. The SOC therapy in this study is offloading of the DFU (CAM boots or total contact casting [TCC] if the subject's foot is too large for a CAM), appropriate sharp or surgical debridement, infection management (systemic antibiotics only in conjunction with debridement) and wound care covering with calcium alginate Fibracol dressing followed by a moisture retentive dressing and a padded 3-layer dressing comprised of 4x4 gauze pads, soft roll and compressive wrap (DynaflexTM or equivalent).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Human Autologous Homologous Skin Construct (SkinTE™) SkinTE™, is an autologous, homologous, FDA-registered, cutaneous human cellular and tissue-based product (HCT/P) that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a diabetic foot wound in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing |
Other: Human Autologous Homologous Skin Construct
Application of a autologous human derived skin polar units
Other Names:
Other: Additional Outer Dressing Applicaiton
Application of Moisture retentive dressing, and a multi-layer compression dressing
Other Names:
Other: Offloading
Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
Other Names:
|
| Active Comparator: Fibracol Wound Dressing A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing |
Other: Additional Outer Dressing Applicaiton
Application of Moisture retentive dressing, and a multi-layer compression dressing
Other Names:
Other: Offloading
Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
Other Names:
Other: Fibracol Wound Dressing
Application of Collagen Alginate Dressing
|
Outcome Measures
Primary Outcome Measures
- Percentage of index ulcers healed at 12 weeks [12 weeks]
examine percent of ulcers healed at week twelve
Secondary Outcome Measures
- Percentage area reduction at 4 weeks [4 weeks]
examine percent of wound reduction at 4 weeks
- Percentage area reduction at 6 weeks [6 weeks]
examine percent of wound reduction at 6 weeks
- Percentage area reduction at 8 weeks [8 weeks]
examine percent of wound reduction at 8 weeks
- Percentage are reduction at 12 weeks [12 weeks]
examine percent of wound reduction at 12 weeks
- Improvement in quality of life using Wound Quality of Life Score [12 weeks]
The Wound-QoL, or wound quality of life questionnaire, measures the disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which are always assessed in retrospect to the preceding seven days. This questionnaire will be given to clinical trial participants at each visit, with the scale scores recorded. Each question is scored. Answers to each item are coded with numbers (0='not at all' to 4='very much'). As noted above the score will be reported with a minimam score of "0" and a maximum score of 68
- Change in pain levels during trial, using the FACES pain scales which measure pain on a range of 0-10, zero being no pain and 10 being the most severe pain [12 weeks]
The FACES pain scale will be administered to the clinical trial participants at each visit. The trial participant will select their pain level with a series of faces that correspond to a number between 0 which implies no pain , up to 10 which implies the most severe pain. The scores will be recorded for each clinical trial participant on each visit
- Changes in peripheral neuropathy using Semmes Weinstein Monofilament "10"point discrimination test [12 weeks]
Each clinical trial participant will be examined by the principal investigator with a Semmes Weinstein monofilament wire at 10 points on the study foot, this standardized exam will be scored out of a total of 10 at each visit and recorded
Other Outcome Measures
- Visible Graft Take at each visit [12 weeks]
Examine the take or the bodies ability to accept the Skin TE
Eligibility Criteria
Criteria
Inclusion Criteria:
-
At least 18 years old.
-
Presence of a DFU, Wagner 1 (see Appendix B for definitions), extending at least through the dermis provided it is below the medial aspect of the malleolus.
-
The index ulcer will be the largest ulcer if two or more DFUs are present with the same Wagner grade and will be the only one evaluated in the study. If other ulcerations are present on the same foot they must be more than 2 cm distant from the index ulcer.
-
Index ulcer (i.e. current episode of ulceration) has been present for greater than 4 weeks prior to SV1 and less than 1-year, as of the date the subject consents for study.
-
Index ulcer is a minimum of 1.0 cm2 and a maximum of 25 cm2 at SV1 and TV1.
-
Adequate circulation to the affected foot as documented by a dorsal transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg, or an Ankle Branchial Index (ABI) between 0.7 and 1.3 within 3 months of SV1, using the affected study extremity. As an alternative arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle or a Toe Brachial Index (TBI) of > 0.6 is acceptable.
-
The target ulcer has been offloaded for at least 14 days prior to randomization.
-
Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers or abstinence) during the course of the study and undergo pregnancy tests.
-
Subject understands and is willing to participate in the clinical study and can comply with weekly visits.
-
Subject has read and signed the IRB/IEC approved Informed Consent Form before screening procedures have been completed.
-
The index ulcer has a clean granular base, is free of necrotic debris, and appears to be healthy vascularized tissue at time of placement of treatment product.
Exclusion Criteria:
-
Index ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes.
-
Index ulcer, in the opinion of the investigator, is suspicious for cancer and should undergo an ulcer biopsy to rule out a carcinoma of the ulcer.
-
Subjects on any investigational drug(s) or therapeutic device(s) within 30 days preceding the first Screening Visit (SV1).
-
History of radiation at the ulcer site (regardless of time since last radiation treatment).
-
Index ulcer has been previously treated or will need to be treated with any prohibited therapies, such as chlorhexidine or collagenase. (See Section 7.3 of this protocol for a list of prohibited medications and therapies).
-
Subjects with a history of more than two weeks treatment with immunosuppressants (including systemic corticosteroids > 10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within one month prior to first Screening visit, or who receive such medications during the screening period, or who are anticipated to require such medications during the study.
-
Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment.
-
Osteomyelitis or bone infection, cellulitis, or "active" Charcot's arthropathy of the affected foot near the site of the wound or on the same limb as the index ulcer as verified by X-ray, MRI, or bone biopsy within 30 days prior to randomization if any of the aforementioned conditions are expected. (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision.)
-
Subject is pregnant or breast-feeding.
-
Presence of diabetes with poor metabolic control as documented with an HbA1c ≥12.0 within 30 days of randomization.
-
Subjects with end stage renal disease as evidenced by a serum creatinine of greater than 3.0 mg/dl within 120 days of randomization.
-
Target wound has presence of local active soft tissue infection or Gangrene involving the treatment site.
-
Index ulcer has reduced in area by 30% or more after 14 days of SOC from SV1 to the TV1/randomization visit.
-
In the opinion of the Investigator, evidence of unstable human immunodeficiency virus (HIV), hepatitis B or hepatitis C at screening.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Martinsville Research Institute | Martinsville | Virginia | United States | 23116 |
Sponsors and Collaborators
- PolarityTE
- Professional Education and Research Institute
Investigators
- Principal Investigator: David Armstrong, DPM, MD, PhD, USC / Salsa
Study Documents (Full-Text)
None provided.More Information
Publications
- STE-DFU-01